238 related articles for article (PubMed ID: 26618648)
1. Rho-Associated Kinase Inhibitor Eye Drop (Ripasudil) Transiently Alters the Morphology of Corneal Endothelial Cells.
Okumura N; Okazaki Y; Inoue R; Nakano S; Fullwood NJ; Kinoshita S; Koizumi N
Invest Ophthalmol Vis Sci; 2015 Nov; 56(12):7560-7. PubMed ID: 26618648
[TBL] [Abstract][Full Text] [Related]
2. Effect of the Rho-Associated Kinase Inhibitor Eye Drop (Ripasudil) on Corneal Endothelial Wound Healing.
Okumura N; Okazaki Y; Inoue R; Kakutani K; Nakano S; Kinoshita S; Koizumi N
Invest Ophthalmol Vis Sci; 2016 Mar; 57(3):1284-92. PubMed ID: 26998714
[TBL] [Abstract][Full Text] [Related]
3. Morphological Changes of Human Corneal Endothelial Cells after Rho-Associated Kinase Inhibitor Eye Drop (Ripasudil) Administration: A Prospective Open-Label Clinical Study.
Nakagawa H; Koizumi N; Okumura N; Suganami H; Kinoshita S
PLoS One; 2015; 10(9):e0136802. PubMed ID: 26367375
[TBL] [Abstract][Full Text] [Related]
4. Potential Functional Restoration of Corneal Endothelial Cells in Fuchs Endothelial Corneal Dystrophy by ROCK Inhibitor (Ripasudil).
Schlötzer-Schrehardt U; Zenkel M; Strunz M; Gießl A; Schondorf H; da Silva H; Schmidt GA; Greiner MA; Okumura N; Koizumi N; Kinoshita S; Tourtas T; Kruse FE
Am J Ophthalmol; 2021 Apr; 224():185-199. PubMed ID: 33316261
[TBL] [Abstract][Full Text] [Related]
5. Descemet Stripping Only Supplemented With Topical Ripasudil for Fuchs Endothelial Dystrophy 12-Month Outcomes of the Sydney Eye Hospital Study.
Moloney G; Garcerant Congote D; Hirnschall N; Arsiwalla T; Luiza Mylla Boso A; Toalster N; D'Souza M; Devasahayam RN
Cornea; 2021 Mar; 40(3):320-326. PubMed ID: 32740006
[TBL] [Abstract][Full Text] [Related]
6. Descemetorhexis Without Grafting for Fuchs Endothelial Dystrophy-Supplementation With Topical Ripasudil.
Moloney G; Petsoglou C; Ball M; Kerdraon Y; Höllhumer R; Spiteri N; Beheregaray S; Hampson J; DʼSouza M; Devasahayam RN
Cornea; 2017 Jun; 36(6):642-648. PubMed ID: 28476048
[TBL] [Abstract][Full Text] [Related]
7. Rho-associated kinase inhibitor eye drop treatment as a possible medical treatment for Fuchs corneal dystrophy.
Koizumi N; Okumura N; Ueno M; Nakagawa H; Hamuro J; Kinoshita S
Cornea; 2013 Aug; 32(8):1167-70. PubMed ID: 23715376
[TBL] [Abstract][Full Text] [Related]
8. Use of Topical Rho Kinase Inhibitors in the Treatment of Fuchs Dystrophy After Descemet Stripping Only.
Macsai MS; Shiloach M
Cornea; 2019 May; 38(5):529-534. PubMed ID: 30720541
[TBL] [Abstract][Full Text] [Related]
9. New therapeutic modality for corneal endothelial disease using Rho-associated kinase inhibitor eye drops.
Koizumi N; Okumura N; Ueno M; Kinoshita S
Cornea; 2014 Nov; 33 Suppl 11():S25-31. PubMed ID: 25289721
[TBL] [Abstract][Full Text] [Related]
10. The ROCK inhibitor eye drop accelerates corneal endothelium wound healing.
Okumura N; Koizumi N; Kay EP; Ueno M; Sakamoto Y; Nakamura S; Hamuro J; Kinoshita S
Invest Ophthalmol Vis Sci; 2013 Apr; 54(4):2493-502. PubMed ID: 23462749
[TBL] [Abstract][Full Text] [Related]
11. A Close Look at the Clinical Efficacy of Rho-Associated Protein Kinase Inhibitor Eye Drops for Fuchs Endothelial Corneal Dystrophy.
Kinoshita S; Colby KA; Kruse FE
Cornea; 2021 Oct; 40(10):1225-1228. PubMed ID: 34481406
[TBL] [Abstract][Full Text] [Related]
12. Effects of ripasudil hydrochloride hydrate (K-115), a Rho-kinase inhibitor, on ocular blood flow and ciliary artery smooth muscle contraction in rabbits.
Ohta Y; Takaseki S; Yoshitomi T
Jpn J Ophthalmol; 2017 Sep; 61(5):423-432. PubMed ID: 28653193
[TBL] [Abstract][Full Text] [Related]
13. Vascular Normalization by ROCK Inhibitor: Therapeutic Potential of Ripasudil (K-115) Eye Drop in Retinal Angiogenesis and Hypoxia.
Yamaguchi M; Nakao S; Arita R; Kaizu Y; Arima M; Zhou Y; Kita T; Yoshida S; Kimura K; Isobe T; Kaneko Y; Sonoda KH; Ishibashi T
Invest Ophthalmol Vis Sci; 2016 Apr; 57(4):2264-76. PubMed ID: 27124322
[TBL] [Abstract][Full Text] [Related]
14. Changes in corneal endothelial cell shape after treatment with one drop of ROCK inhibitor.
Matsumura R; Inoue K; Shiokawa M; Ono M; Tanihara H; Ishida K; Tomita G
Int Ophthalmol; 2020 Feb; 40(2):411-417. PubMed ID: 31664638
[TBL] [Abstract][Full Text] [Related]
15. Rho kinase (ROCK) inhibitors in the management of corneal endothelial disease.
Syed ZA; Rapuano CJ
Curr Opin Ophthalmol; 2021 May; 32(3):268-274. PubMed ID: 33606407
[TBL] [Abstract][Full Text] [Related]
16. Effect of the Rho Kinase Inhibitor Y-27632 on Corneal Endothelial Wound Healing.
Okumura N; Inoue R; Okazaki Y; Nakano S; Nakagawa H; Kinoshita S; Koizumi N
Invest Ophthalmol Vis Sci; 2015 Sep; 56(10):6067-74. PubMed ID: 26393474
[TBL] [Abstract][Full Text] [Related]
17. Morphological change and recovery of corneal endothelial cells after rho-associated protein kinase inhibitor eye-drop (ripasudil 0.4%) instillation.
Maruyama Y; Ikeda Y; Mori K; Yoshii K; Ueno M; Yoshikawa H; Sotozono C; Kinoshita S
Br J Ophthalmol; 2021 Feb; 105(2):169-173. PubMed ID: 32269062
[TBL] [Abstract][Full Text] [Related]
18. [Morphologic characteristics of cornea in Fuchs endothelial dystrophy observed by confocal microscopy].
Dong WL; Zou LH; Pan ZQ; Wang L
Zhonghua Yan Ke Za Zhi; 2004 Jul; 40(7):465-70. PubMed ID: 15454061
[TBL] [Abstract][Full Text] [Related]
19. An update on ripasudil for the treatment of glaucoma and ocular hypertension.
Testa V; Ferro Desideri L; Della Giustina P; Traverso CE; Iester M
Drugs Today (Barc); 2020 Sep; 56(9):599-608. PubMed ID: 33025953
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of Rho-associated protein kinase activity enhances oxidative phosphorylation to support corneal endothelial cell migration.
Ho WT; Chang JS; Chen TC; Wang JK; Chang SW; Yang MH; Jou TS; Wang IJ
FASEB J; 2022 Jul; 36(7):e22397. PubMed ID: 35661268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
